Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.
It is important for health systems to improve accessibility and affordability for treatments for HIV and potential comorbidities, because those related problems can be associated with a patient's ability to adhere to their treatment, said Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope.
Transcript
How can health systems address patient accessibility and affordability issues associated with HIV therapies?
HIV medications are expensive, and in the United States the total annual undiscounted spending on antiretroviral drugs has more than doubled since 2010, reaching over $22 billion in 2018. Sustained regular care for people living with HIV, which includes starting therapy and maintaining therapy, is vital to their general health. This also prevents further transmission of the virus because people who are living with HIV who are on effective treatment who have effectively undetectable viral loads can't transmit the virus to others. HIV-infected patients who are receiving ongoing regular scheduled care in general do better. They have significantly lower viral loads and higher CD4 cells or, in general, better functioning immune systems. They also have decreased morbidity and mortality, and this also helps lower rates of progression to other complications, including AIDS, or hospitalizations associated with comorbidities associated with HIV and AIDS and, in general, overall improved health.
So one important way for health care systems to address this is to really improve access to care for these patients. And care should be comprehensive. Many of these patients are at risk for some long-term comorbidities associated with their HIV. Some of these comorbidities are associated with aging, and that includes cardiovascular disease, neurologic diseases, metabolic diseases, and cancer. For them to have access to [treatment for] these health issues is important, but it's also important for them to have access to [treatment for] any issues that may also be associated with psychiatric issues or substance abuse, because those problems can also be associated with their ability to take their medications on a regular basis.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More